164 related articles for article (PubMed ID: 15983738)
1. Successful treatment of antifungal- and cryotherapy-resistant subcutaneous hyalohyphomycosis in an immunocompetent case with topical 5% imiquimod cream.
Erbagci Z; Tuncel AA; Erkilic S; Zer Y
Mycopathologia; 2005 Jun; 159(4):521-6. PubMed ID: 15983738
[TBL] [Abstract][Full Text] [Related]
2. Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.
Badavanis G; Pasmatzi E; Monastirli A; Georgiou S; Tsambaos D
Acta Dermatovenerol Croat; 2017 Jul; 25(2):164-166. PubMed ID: 28871935
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases.
Erbagci Z; Tuncel AA; Erbagci I
J Drugs Dermatol; 2006; 5(7):668-71. PubMed ID: 16865875
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in an immunocompetent host successfully treated with itraconazole: case report and review.
Gutiérrez-Rodero F; Moragón M; Ortiz de la Tabla V; Mayol MJ; Martín C
Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):814-8. PubMed ID: 10614958
[TBL] [Abstract][Full Text] [Related]
5. Novel dermatologic uses of the immune response modifier imiquimod 5% cream.
Berman B; Poochareon VN; Villa AM
Skin Therapy Lett; 2002 Nov; 7(9):1-6. PubMed ID: 12548325
[TBL] [Abstract][Full Text] [Related]
6. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod.
Brown CW; O'Donoghue M; Moore J; Tharp M
Cutis; 2000 Jun; 65(6):363-6. PubMed ID: 10879304
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod in the treatment of cutaneous warts: an evidence-based review.
Ahn CS; Huang WW
Am J Clin Dermatol; 2014 Oct; 15(5):387-99. PubMed ID: 25186654
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study.
Saiag P; Bauhofer A; Bouscarat F; Aquilina C; Ortonne JP; Dupin N; Mougin C
Br J Dermatol; 2009 Oct; 161(4):904-9. PubMed ID: 19466962
[TBL] [Abstract][Full Text] [Related]
9. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus.
Cutler K; Kagen MH; Don PC; McAleer P; Weinberg JM
Acta Derm Venereol; 2000; 80(2):134-5. PubMed ID: 10877136
[TBL] [Abstract][Full Text] [Related]
10. Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review.
Perkins N; Nisbet M; Thomas M
Sex Transm Infect; 2011 Jun; 87(4):292-5. PubMed ID: 21406577
[TBL] [Abstract][Full Text] [Related]
11. Acremonium species: a review of the etiological agents of emerging hyalohyphomycosis.
Das S; Saha R; Dar SA; Ramachandran VG
Mycopathologia; 2010 Dec; 170(6):361-75. PubMed ID: 20577905
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous hyalohyphomycosis caused by Acremonium in an immunocompetent patient.
Kan SF; Tsai TH; Hu CH; Lee WR
Br J Dermatol; 2004 Apr; 150(4):789-90. PubMed ID: 15099392
[No Abstract] [Full Text] [Related]
13. Topical imiquimod for recalcitrant facial flat warts.
Schwab RA; Elston DM
Cutis; 2000 Mar; 65(3):160-2. PubMed ID: 10738635
[TBL] [Abstract][Full Text] [Related]
14. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others.
Tortorano AM; Richardson M; Roilides E; van Diepeningen A; Caira M; Munoz P; Johnson E; Meletiadis J; Pana ZD; Lackner M; Verweij P; Freiberger T; Cornely OA; Arikan-Akdagli S; Dannaoui E; Groll AH; Lagrou K; Chakrabarti A; Lanternier F; Pagano L; Skiada A; Akova M; Arendrup MC; Boekhout T; Chowdhary A; Cuenca-Estrella M; Guinea J; Guarro J; de Hoog S; Hope W; Kathuria S; Lortholary O; Meis JF; Ullmann AJ; Petrikkos G; Lass-Flörl C; ;
Clin Microbiol Infect; 2014 Apr; 20 Suppl 3():27-46. PubMed ID: 24548001
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient.
Strauss RM; Doyle EL; Mohsen AH; Green ST
Int J STD AIDS; 2001 Apr; 12(4):264-6. PubMed ID: 11319979
[TBL] [Abstract][Full Text] [Related]
16. The use of topical imiquimod for the treatment of actinic keratosis: a status report.
Del Rosso JQ
Cutis; 2005 Oct; 76(4):241-8. PubMed ID: 16315560
[TBL] [Abstract][Full Text] [Related]
17. 5% topical imiquimod tolerance in transplant recipients.
Ben M'barek L; Mebazaa A; Euvrard S; Frances C; Thervet E; Morel P; Menasché S; Legendre C; Lebbe C
Dermatology; 2007; 215(2):130-3. PubMed ID: 17684375
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous hyalohyphomycosis caused by Acremonium recifei: case report.
Zaitz C; Porto E; Heins-Vaccari EM; Sadahiro A; Ruiz LR; Müller H; Lacaz Cda S
Rev Inst Med Trop Sao Paulo; 1995; 37(3):267-70. PubMed ID: 8525275
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals.
Harwood CA; Perrett CM; Brown VL; Leigh IM; McGregor JM; Proby CM
Br J Dermatol; 2005 Jan; 152(1):122-9. PubMed ID: 15656812
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
Akkilic-Materna M; Massone C; Komericki P
Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
